CompletedPhase 1

Intralymphatic Immunotherapy for House Dust Mite, Dog, and Cat Allergy Using Tyrosine S® in Allergic Rhinitis

South Korea32 participantsStarted 2016-07

Plain-language summary

The investigators will perform double-blinded placebo-controlled randomized clinical trial which evaluates the efficacy and safety of allergen-specific intralymphatic immunotherapy (ILIT) for allergens including Dermatophagoides farinae (Df), Dermatophagoides pteronyssinus (Dp), cat, and dog that are sensitized and provoke rhinitis-related symptoms in patients with allergic rhinitis (AR), using allergen extracts for allergen-specific immunotherapy (Tyrosine S, Allergy Therapeutic, West Sussex, UK).

Who can participate

Age range19 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Sensitization should be verified by skin prick test and the level of serum specific IgE measured by ImmunoCAP® (Thermo Fisher Scientific, Uppsala, Sweden).
✓. Subjects should complain of AR symptoms during exposure of house dust, dog and/or cat in daily life.

Exclusion criteria

✕. Uncontrolled or severe asthma according to Global Initiative of Asthma (GINA) guideline including a case in which forced expiratory volume in 1 s (FEV1) was less than 50% of predicted value
✕. Significant cardiovascular, hepatic, renal, hematologic, oncologic, or infectious diseases
✕. Administration of beta blocker, angiotensin converting enzyme inhibitor, tricyclic antidepressant, immunosuppressant including systemic glucocorticosteroid within last 2 weeks
✕. AR caused by other perennial or seasonal allergen
✕. Prior history of allergen-specific immunotherapy
✕. Rejection or low compliance,
✕. Pregnancy or lactation
✕. Vulnerable volunteer

What they're measuring

RQLQ

Timeframe: 4 months after the day of first injection of ILIT

Trial details

NCT IDNCT02665754

SponsorGachon University Gil Medical Center

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-12

View on ClinicalTrials.gov More Allergic Rhinitis trials